Skip to main content

Bain Linda's Form 4 filing

Codiak BioSciences, Inc. (CDAK) · filed Feb 21, 2023

Accession no.
0000899243-23-005697
Filed
Feb 21, 2023
Trade date
Aug 16, 2022-Feb 17, 2023
Filing delay
189 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.74K. It was filed 189 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bain LindaCIK 0001578407Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2022Common StockMOption exerciseAcquired+7,613––10,733Direct
Aug 17, 2022Common StockSSaleDisposed−2,364$2.21−$5,224.448,369Direct
Feb 16, 2023Common StockMOption exerciseAcquired+7,613––15,982Direct
Feb 17, 2023Common StockSSaleDisposed−2,570$0.59−$1,516.313,412Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 16, 2022Common StockMOption exerciseDisposed−7,613$0.00$022,837Direct
Feb 16, 2023Common StockMOption exerciseDisposed−7,613$0.00$015,224Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)